|
Jul 25
|
How To Earn $100 Per Month From Pfizer Stock
|
|
Jul 25
|
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
|
|
Jul 25
|
Patience Could Be Rewarded With Moat Investing
|
|
Jul 25
|
Seeking Clues to Pfizer (PFE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
|
|
Jul 25
|
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
|
|
Jun 24
|
Britain snubs GSK in favour of US pharma giant for RSV vaccine
|
|
Jun 24
|
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
|
|
Jun 24
|
Did Seagen Acquisition Help Pfizer Inc. (PFE) Increase Revenue in Q1?
|
|
Jun 24
|
2 Beaten-Down Growth Stocks to Buy Without Hesitation in the 2024 Bull Market
|
|
Jun 24
|
Alnylam says heart drug succeeds in closely watched study
|
|
Jun 23
|
Want an Extra $100 in Annual Dividend Income? Invest $1,320 in These 3 High-Yield Stocks
|
|
Jun 22
|
The Most Populated Country in the World
|
|
Jun 22
|
3 No-Brainer Stocks to Buy for Under $100 Right Now
|
|
Jun 22
|
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
|
|
Jun 21
|
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
|
|
Jun 21
|
Sarepta’s Elevidys secures US label expansion for DMD
|
|
Jun 21
|
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
|
|
Jun 21
|
Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.
|
|
Jun 21
|
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
|
|
Jun 21
|
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
|